{
  "ticker": "LLY",
  "target_date": "2025-01-13",
  "actual_date": "2025-01-13",
  "collected_at": "2025-12-08T11:16:09.401904",
  "price": {
    "open": 788.52,
    "high": 799.38,
    "low": 777.81,
    "close": 791.57568359375,
    "volume": 3683800,
    "change_1d_pct": -0.3,
    "change_7d_pct": 3.3,
    "change_30d_pct": 1.03
  },
  "technicals": {
    "rsi_14": 65.71,
    "sma_20": 775.08,
    "sma_50": 782.97,
    "macd": -2.475,
    "macd_signal": -5.688,
    "macd_histogram": 3.213,
    "bb_upper": 799.25,
    "bb_lower": 750.91,
    "price_vs_sma20_pct": 2.13,
    "price_vs_sma50_pct": 1.1,
    "volume_ratio": 1.13
  },
  "fundamentals": {
    "market_cap": 890446020608,
    "pe_ratio": 48.667076,
    "forward_pe": 43.834732,
    "price_to_book": 37.398155,
    "price_to_sales": 14.985679,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.67,
    "pct_from_52w_low": 59.24
  },
  "macro": {
    "spy": {
      "price": 576.34,
      "change_1d_pct": 0.16,
      "change_7d_pct": -0.56
    },
    "vix": {
      "level": 19.19,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.8
    },
    "dollar_index": {
      "level": 109.96
    },
    "gold": {
      "price": 2673.5
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
      "source": "SeekingAlpha",
      "datetime": 1736791802,
      "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
      "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835"
    },
    {
      "headline": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "source": "MarketWatch",
      "datetime": 1736785860,
      "summary": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=5ca1a4ed02d4da6be717721fe376a6df28d2c8195225538227c87b1676a40ab6"
    },
    {
      "headline": "Lilly asks US government to pause drug price negotiation program, Bloomberg News reports",
      "source": "Finnhub",
      "datetime": 1736775043,
      "summary": "Eli Lilly has asked the U.S. government to pause the new law that allows Medicare to negotiate prices for its costliest prescription drugs, Bloomberg News reported on Monday, citing Lilly Chief...",
      "url": "https://finnhub.io/api/news?id=8d5363c04f4ac503e8c1f4f1f91767a7954bed52c7f7e6227e84c0634341443a"
    },
    {
      "headline": "Johnson & Johnson makes $15 billion bet on mental-health drugs",
      "source": "MarketWatch",
      "datetime": 1736770500,
      "summary": "Johnson & Johnson makes $15 billion bet on mental-health drugs",
      "url": "https://finnhub.io/api/news?id=35f7f11489d2dd65b5f0ad8661db1e6bbf02ca68fe03f5836e3199a0176a3619"
    },
    {
      "headline": "Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing",
      "source": "Finnhub",
      "datetime": 1736767814,
      "summary": "-- Eli Lilly & Co. Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill...",
      "url": "https://finnhub.io/api/news?id=c0192b18c69c77dbed4053a7ccb4ceb9486136b502394ca0f58a4e1683eb0aab"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470584.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000291/xslF345X05/wk-form4_1734470584.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470498.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000289/xslF345X05/wk-form4_1734470498.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470366.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000287/xslF345X05/wk-form4_1734470366.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470270.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000285/xslF345X05/wk-form4_1734470270.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470180.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000283/xslF345X05/wk-form4_1734470180.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}